HealthcareServices

Global Primary Immunodeficiency Disorders Market Set for Strong Expansion, Reaching $10.01 Billion With 6.5% CAGR by 2030

March 2, 2026March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the primary immunodeficiency disorders market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Primary Immunodeficiency Disorders Market be in 2030 compared with 2026?

The primary immunodeficiency disorders market size has experienced substantial expansion in recent years. It is projected to increase from $7.3 billion in 2025 to $7.79 billion in 2026, progressing at a compound annual growth rate (CAGR) of 6.8%. This historical growth can be ascribed to several factors, including enhanced clinical identification of immunodeficiency disorders, broadened diagnostic testing capabilities, greater awareness among healthcare professionals, the provision of immunoglobulin therapies, and the establishment of more specialized treatment centers.

The market for primary immunodeficiency disorders is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $10.01 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.5%. Key drivers for this expansion during the forecast period include greater progress in gene therapy research, an escalating need for timely and precise diagnosis, the broadening availability of precision immunology treatments, increased funding for rare disease research, and the expanding incorporation of AI within diagnostic processes. Significant trends anticipated over the same period encompass the wider embrace of genetic testing for early detection, the increasing application of immunoglobulin replacement therapies, a heightened emphasis on individualized treatment strategies, the scaling up of newborn screening initiatives, and the improved integration of sophisticated diagnostic platforms.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23483&type=smp

What Drivers Are Guiding Growth Patterns In The Primary Immunodeficiency Disorders Market?

The increasing occurrence of autoimmune conditions is anticipated to fuel the expansion of the primary immunodeficiency disorders market in the future. Autoimmune diseases manifest when the body’s immune system erroneously attacks its own healthy cells and tissues, perceiving them as threats. This aberrant reaction results in inflammation and damage across various organs and bodily systems. The surge in autoimmune diseases is linked to a complex combination of environmental factors, genetic predispositions, and shifts in lifestyle. These conditions can lead to primary immunodeficiency disorders by disrupting immune regulation and targeting immune cells, which weakens or impairs immune responses. For instance, in February 2024, according to Arthritis Australia, an Australia-based charitable not-for-profit organisation advocating for people with arthritis and musculoskeletal conditions, by 2025, approximately 562,378 Australians are living with rheumatoid arthritis (RA), accounting for 14% of the total arthritis population. Consequently, the growing prevalence of autoimmune diseases is driving the growth of the primary immunodeficiency disorders market.

Which Segments Are Driving Activity In The Primary Immunodeficiency Disorders Market?

The primary immunodeficiency disorders market covered in this report is segmented –

1) By Disease: Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders, Other Diseases

2) By Treatment: Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell And Bone Marrow Transplantation, Gene Therapy, Other Treatments

3) By Diagnostic Type: Genetic Testing, Blood Testing, Flow Cytometry, Other Diagnostic Types

4) By End-User: Hospitals, Specialty Clinics, Homecare Settings, Research Institutions

Subsegments:

1) By Antibody Deficiency: Common Variable Immune Deficiency (CVID), IgA Deficiency, IgG Subclass Deficiency, Specific Antibody Deficiency

2) By Cellular Immunodeficiency: Severe Combined Immunodeficiency (SCID), T-Cell Deficiency, DiGeorge Syndrome, Wiskott-Aldrich Syndrome

3) By Innate Immune Disorders: Chronic Granulomatous Disease (CGD), Complement Deficiencies, Toll-like Receptor Deficiencies, Chediak-Higashi Syndrome

4) By Other Diseases: Hyper IgM Syndrome, Hyper IgE Syndrome, Ataxia-Telangiectasia, Combined Immunodeficiencies With Syndromic Features

Which Trends Are Shaping Activity Within The Primary Immunodeficiency Disorders Market?

Leading companies in the primary immunodeficiency disorders market are concentrating on developing advanced treatments, such as intravenous immunoglobulin therapy, to improve patient outcomes by enhancing immune function. Intravenous immunoglobulin (IVIG) therapy is a medical procedure where immunoglobulin (antibodies) obtained from donor plasma is directly administered into a patient’s bloodstream via an IV. For example, in June 2024, Grifols, a Spain-based healthcare firm, gained FDA approval for Yimmugo, an intravenous immunoglobulin (IVIg) therapy. This new, sugar-free, ready-to-use IgG solution is derived from human blood plasma and designed for intravenous application. Approved in the U.S. for substitution therapy in individuals with primary antibody deficiency syndromes, Yimmugo delivers antibody replacement to assist those with immune system deficiencies. It expands Grifols’ range of plasma-based treatments by providing a safer and more effective choice to aid in protection against infections.

Which Leading Companies Dominate The Primary Immunodeficiency Disorders Market Share?

Major companies operating in the primary immunodeficiency disorders market are Pfizer Inc, Takeda Pharmaceuticals, CSL Behring, Baxter International Inc, Grifols SA, Octapharma, Kedrion Biopharma, LFB Group, ADMA Biologics Inc, Bio Products Laboratory Ltd, Miltenyi Biotec, BD Biosciences, Cellectis SA, X4 Pharmaceuticals Inc, bluebird bio Inc, Chengdu Rongsheng Pharmaceutical Co Ltd, Sanofi SA, Roche Holding AG, Novartis AG, AbbVie Inc, AstraZeneca plc, Gilead Sciences Inc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/primary-immunodeficiency-disorders-global-market-report

How Does The Primary Immunodeficiency Disorders Market Perform Across Major Global Regions?

North America was the largest region in the primary immunodeficiency disorders market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary immunodeficiency disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Primary Immunodeficiency Disorders Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23483&type=smp

Browse Through More Reports Similar to the Global Primary Immunodeficiency Disorders Market 2026, By The Business Research Company

Immunodiagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunodiagnostics-global-market-report

Immunoassay Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report

Acne Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/acne-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795